Obesity

Study links prediabetes remission to lower diabetes risk without weight loss

8. oktober 2025 Rapportert av AI

Researchers in Tübingen have found that people with prediabetes can reduce their risk of developing type 2 diabetes by 71% through lifestyle changes that normalize blood sugar levels, even if they do not lose weight. The study emphasizes the role of improved fat distribution over mere weight reduction. This challenges current guidelines focused primarily on shedding pounds.

Higher semaglutide dose boosts weight loss in obesity trials

Two phase 3 clinical trials show that a 7.2 mg weekly dose of semaglutide leads to greater weight loss than the approved 2.4 mg dose in adults with obesity, including those with type 2 diabetes. Nearly half of participants on the higher dose lost 20% or more of their body weight over 72 weeks. The results, published in The Lancet Diabetes & Endocrinology, suggest improved metabolic health with a favorable safety profile.

Study highlights disparities in obesity care access

4. oktober 2025 Rapportert av AI

A recent analysis reveals significant gaps in obesity treatment for certain demographic groups in the United States. Researchers found that access to care varies widely based on race, income, and location, underscoring ongoing challenges in healthcare equity.

End of patent protection for weight loss injections benefits patients

3. oktober 2025 Rapportert av AI

Patent protection for semaglutide in weight loss injections like Ozempic and Wegovy is expiring in Europe. This paves the way for cheaper generics to enter the market and could lower high prices. Patients with obesity stand to benefit from improved access.

Scientists discover protein that switches off hunger